Ńjẹ́rìísi...
A túmọ̀ rẹ̀ láìfọwọ́yí. Fún ìwọ̀n oògùn àti ìkìlọ̀: wo ẹ̀dà Gẹ̀ẹ́sì àkọ́kọ́. Ka ní Gẹ̀ẹ́sì

Norpiflex Tablet

NAFDAC Reg. Rárá. B4-6601 · Oògùn

Forukọsilẹ pẹlu NAFDAC. Iforukọsilẹ ti nṣiṣe lọwọAs of 5 November 2026 · synced automatically from official sources.
Ọja
Norpiflex Tablet
Nọmba NAFDAC
B4-6601
Ohun elo ti nṣiṣe lọwọ
Orphenadrine Citrate
Agbara
100 mg
Fọọmu
Tablet
Iwọn iṣakojọpọ
2 x 10's (in blisters)
Olupese
Ko ṣe atokọ
Olubẹwẹ (oluranlowo)
C' D-Demeris Pharmaceuticals Limited
Ti fọwọsi
28 Feb 2025
Ipò
Nṣiṣẹ Wo lórí NAFDAC ↗
Iforukọsilẹ wulo si
27 Feb 2030
Tani o ṣe itaniji
Kosi ikankan ti a rii.
Ijabọ Agbegbe
Kò sí
Àwọn àyẹ̀wò àsìkò
0

What we found

  • Norpiflex Tablet is on the NAFDAC register with an active registration (B4-6601). A valid number alone does not prove a pack is genuine — counterfeiters copy real numbers, so also check the expiry date, seal and print quality.

Generated automatically from the NAFDAC register, WHO alerts and community data as of today. This is not medical advice. Always follow your doctor or pharmacist.

How to use Norpiflex Tablet

What the official label says. If a doctor prescribed it, follow the prescription. Your pack's leaflet comes first if it is different.

Tani o jẹ fun

Orphenadrine citrate extended-release tablets are indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute painful musculoskeletal conditions.

Bii o ṣe le mu u ati igba melo ni

Adults Two tablets per day; one in the morning and one in the evening.

Children
  • Safety and effectiveness
  • In pediatric patients have not been established
Talk to a doctor first if
  • Orphenadrine citrate extended-release tablets are contraindicated in patients with glaucoma, pyloric or duodenal obstruction, stenosing peptic ulcers, prostatic hypertrophy or obstruction of the bladder neck, cardio-spasm (mega-esophagus) and myasthenia gravis
  • Orphenadrine citrate tablets are contraindicated in patients who have demonstrated a previous hypersensitivity to the drug
Warnings

Some patients may experience transient episodes of light-headedness, dizziness or syncope. Orphenadrine may impair the ability of the patient to engage in potentially hazardous activities such as operating machinery or driving a motor vehicle; ambulatory patients should therefore be cautioned accordingly.

Àbájáde tí ó ṣeéṣe

Adverse reactions of orphenadrine are mainly due to the mild anticholinergic action of orphenadrine, and are usually associated with higher dosage. Dryness of the mouth is usually the first adverse effect to appear. When the daily dose is increased, possible adverse effects include: tachycardia, palpitation, urinary hesitancy or retention, blurred vision, dilatation of pupils, increased ocular tension, weakness, nausea, vomiting, headache, dizziness, constipation, drowsiness, hypersensitivity reactions, pruritus, hallucinations, agitation, tremor, gastric irritation, and rarely urticaria and other dermatoses. Infrequently, an elderly patient may experience some degree of mental confusion. …

Pregnancy and breastfeeding

Pregnancy Pregnancy Category C Animal reproduction studies have not been conducted with orphenadrine. It is also not known whether orphenadrine can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Orphenadrine should be given to a pregnant woman only if clearly needed.

If you take too much

Orphenadrine is toxic when overdosed and typically induces anticholinergic effects. In a review of orphenadrine toxicity, the minimum lethal dose was found to be 2 to 3 grams for adults; however, the range of toxicity is variable and unpredictable. Treatment for orphenadrine overdose is evacuation of stomach contents (when necessary), charcoal at repeated doses, intensive monitoring, and appropriate supportive treatment of any emergent anticholinergic effects.

Dependence and misuse

Orphenadrine has been chronically abused for its euphoric effects. The mood elevating effects may occur at therapeutic doses of orphenadrine.

If you miss a dose

Take it when you remember, unless it is nearly time for the next dose. Then skip the missed one. Never take two doses at once to make up for it. Check your leaflet, as some medicines are different.

From the official U.S. FDA label for this active ingredient. Your pack may have a different strength, so always read its leaflet. If a doctor prescribed it, follow the prescription. Ask a pharmacist if you are unsure. Label dated 2026-01-01.

Label for orphenadrine citrate, the active ingredient registered with NAFDAC.

Check your pack of Norpiflex Tablet

Add the expiry date on your pack for a full Trust Score.

Or take photos of the pack
3 free checks left today Official sources: U.S. FDA · EMA (EU) · Health Canada · WHO alerts

About Norpiflex Tablet

What is in Norpiflex Tablet?

Norpiflex Tablet contains Orphenadrine Citrate (100 mg), as tablet, according to its NAFDAC registration record.

Is Norpiflex Tablet registered with NAFDAC?

Yes. Norpiflex Tablet is listed on the NAFDAC register under registration number B4-6601, and its registration is active as of 5 November 2026.

Has Norpiflex Tablet been flagged as fake or recalled?

No WHO falsified or substandard medical product alert currently matches Norpiflex Tablet in our automatically synced alert list.

How can I check that my pack of Norpiflex Tablet is genuine?

Run a free authenticity scan with the NAFDAC number B4-6601, your pack's expiry date and batch number to get a Trust Score, compare the pack with the NAFDAC record (ingredient, strength, form, manufacturer), and buy only from licensed pharmacies.

How do I take Norpiflex Tablet?

Follow your prescription or the leaflet in your pack. The official label says: Adults Two tablets per day; one in the morning and one in the evening.…

What is Norpiflex Tablet used for?

Orphenadrine citrate extended-release tablets are indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute painful musculoskeletal conditions. (Summarised from the official U.S. FDA label for orphenadrine citrate. Always follow your doctor or pharmacist.)

Patient reviews

–No reviews yet
5★
0
4★
0
3★
0
2★
0
1★
0
Have you used Norpiflex Tablet? Share your experience to help other patients. Sign in to review

Reviews are personal experiences from PillVera users, not medical advice. Report side effects to your doctor and to NAFDAC.